Skip to main content
. 2016 Sep 2;38(5-6):379–391. doi: 10.1007/s11357-016-9948-4

Table 6.

Necropsy results for the ramipril-treated and control mice shown in Fig. 1c

Organ Pathology Dietary treatment
Control (n = 36)a Ramipril (n = 36)
No.b (%)c No. (%) P valued
Spleen Enlarged/tumorous 19 70.4 16 59.3 0.569
Liver Hemangioma 0 0.0 0 0.0 1.000
Enlarged/fatty liver 1 3.7 1 3.7 1.000
Tumor 18 66.7 11 40.7 0.101
Intestine Tumor 2 7.4 1 3.7 1.000
Lung Tumor 19 70.4 12 44.4 0.098
Penis Necrosed/inflamed 0 0.0 1 3.7 1.000
Seminal vesicle Enlarged 2 7.4 1 3.7 1.000
Bladder Distended 1 3.7 1 3.7 1.000
Kidney Enlarged/tumorous 2 7.4 1 3.7 1.000
Thymus Enlarged 5 18.5 7 25.9 0.7445
Skin/abdominal cavity Fibroma 4 14.8 6 22.2 0.7277
Body cavity Hemorrhage 7 25.9 9 33.3 0.7664
Thorax only Hemorrhage 8 29.6 3 11.1 0.1751
Body cavity and thorax Hemorrhage 15 55.6 12 44.4 0.5867

aNumber of necropsied mice in each group. All deceased mice were necropsied. The necropsied control mice were chosen to approximate the ages at death of the ramipril-treated mice

bThe number of necropsied mice with each pathology

cThe percent of the necropsied mice in each group with the indicated pathologies

dFisher’s exact test was utilized to investigate the association between the pathologies and ramipril treatment. The P values are two-sided. No significant differences were found